Fiche du document
2018
- doi: 10.7573/dic.212527
- issn: 1740-4398
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.7573/dic.212527
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/29872449
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1745-1981
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_91C5DC48B2496
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Patients--Mortality Mortality, Law ofCiter ce document
M. Bassetti et al., « How to manage Pseudomonas aeruginosa infections. », Serveur académique Lausannois, ID : 10.7573/dic.212527
Métriques
Partage / Export
Résumé
Infections with Pseudomonas aeruginosa have become a real concern in hospital-acquired infections, especially in critically ill and immunocompromised patients. The major problem leading to high mortality lies in the appearance of drug-resistant strains. Therefore, a vast number of approaches to develop novel anti-infectives is currently pursued. Diverse strategies range from killing (new antibiotics) to disarming (antivirulence) the pathogen. In this review, selected aspects of P. aeruginosa antimicrobial resistance and infection management will be addressed. Many studies have been performed to evaluate the risk factors for resistance and the potential consequences on mortality and attributable mortality. The review also looks at the mechanisms associated with resistance - P. aeruginosa is a pathogen presenting a large genome, and it can develop a large number of factors associated with antibiotic resistance involving almost all classes of antibiotics. Clinical approaches to patients with bacteremia, ventilator-associated pneumonia, urinary tract infections and skin soft tissue infections are discussed. Antibiotic combinations are reviewed as well as an analysis of pharmacokinetic and pharmacodynamic parameters to optimize P. aeruginosa treatment. Limitations of current therapies, the potential for alternative drugs and new therapeutic options are also discussed.